Considerations To Know About XMU-MP-1
Kantarjian et al53 assessed the efficacy and security of dasatinib, as in contrast with imatinib, for the primary-line treatment method of CML-CP. 5 hundred and nineteen patients with newly diagnosed CML-CP ended up randomly assigned to get dasatinib in a dose of one hundred mg as soon as daily (259 clients) or imatinib at a dose of 400 mg after ev